iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Zydus Lifesciences bags final USFDA approval for Famotidine Injection

23 Nov 2022 , 03:03 PM

The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) final approval to market Famotidine Injection USP, 40 mg/4 mL (10 mg/mL) and 200 mg/20 mL (10 mg/mL) multiple-dose vials.

Famotidine Injection is used to treat stomach and intestine ulcers, as well as to keep intestinal ulcers from returning after they have healed. This medication is also used to treat conditions affecting the stomach and throat (oesophagus), such as erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

According to IQVIA data, Famotidine Injection had annual sales of USD 1.9 million in the United States (IQVIA MAT Sep 2022). The drug will be produced at the group’s injectable manufacturing facility in Jarod, India, near Vadodara.

Since the beginning of the filing process in FY 2003-04, the group has received 333 approvals and has filed over 431 ANDAs.

At around 3.01 PM, Zydus Lifesciences was trading at Rs394.10 up by 0.42% from its previous closing of Rs392.45 on the BSE. The scrip touched intraday high and low of Rs395.30 and Rs390.85 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Cadila Healthcare News
  • Cadila Healthcare Share
  • Cadila Healthcare Stock
  • Cadila Healthcare Updates
  • Zydus Lifesciences Approval
  • Zydus Lifesciences news
  • Zydus Lifesciences Stock
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.